California-based AI biotechnology company Terray Therapeutics has entered into a multi-target collaboration with Google’s anti-aging healthcare company Calico. This collaboration is aimed at developing novel small-molecule therapeutics for age-related diseases including cancer. The terms and financial details of the agreement have not been disclosed.
The duo will research a number of targets proposed by Calico by leveraging Terray’s proprietary computational platform tNova, while Calico will be responsible for the development and commercialization of the candidates. Terray will receive an upfront payment, further milestone payments, and royalties on net sales.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.